Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
(Clinical Trial;Journal Article)
Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.
Moseley, RP; Davies, AG; Richardson, RB; Zalutsky, M; Carrell, S; Fabre, J; Slack, N; Bullimore, J; Pizer, B; Papanastassiou, V
Volume / Issue
Start / End Page
Pubmed Central ID
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)